查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017792

北美真實世界數據解決方案市場規模、佔有率和趨勢分析報告：按組件、應用、最終用途、治療領域、國家和細分市場預測（2026-2033 年）

North America Real World Evidence Solutions Market Size, Share & Trends Analysis Report By Component, By Application, By End Use, By Therapeutic Area, By Country, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

北美真實世界數據解決方案市場概述

預計到 2025 年，北美真實世界數據解決方案市值將達到 13.4 億美元，預計到 2033 年將達到 25.2 億美元，2026 年至 2033 年的複合年成長率為 8.29%。

市場成長的促進因素包括：監管決策中擴大使用真實世界數據、對基於價值的醫療保健的需求不斷成長，以及製藥和生物技術公司需要產生有關其藥物安全性和有效性的上市後證據。

北美真實世界數據 (RWE) 解決方案市場正在成長，這主要得益於監管機構對 RWE 解決方案應用的大力支持，以及生物醫學和轉化研究領域投資的不斷增加。例如，根據美國國家科學與工程統計中心 (NCES) 的數據，2024 年健康科學領域的研發支出將達到 385 億美元，比 2023 年增加 28 億美元。同時，生物科學和生物醫學領域的研發支出將達到 208 億美元，比 2023 年增加 13 億美元。這兩個領域的研發支出合計佔高等教育機構研發總支出的 50%。大學醫院對研究和生命科學投入的增加，促進了真實世界數據、觀察性研究和臨床研究成果的進一步生成，從而提高了對先進的 RWE 分析和證據生成平台的需求。

此外，醫療保健產業從數量驅動到價值驅動的轉變預計將推動市場成長。老年人口的成長和慢性病盛行率的上升也將進一步加速市場擴張。此外，美國和加拿大眾多主要行業參與者的存在也鞏固了該地區的市場地位。有利的政府法規以及該地區真實世界證據（RWE）服務供應商數量的增加預計也將進一步加速市場成長。

本報告預測了2021年至2033年區域和國家層級的收入成長，並分析了各細分市場的最新產業趨勢。在本研究中，Grand View Research根據服務、組件、應用、最終用戶、治療領域和地區對北美真實世界證據（RWE）解決方案市場報告進行了細分：

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：北美真實世界數據解決方案市場：按組件分類的估算和趨勢分析

  • 基於組件的市場佔有率和波動分析，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按組件分類，2021-2033 年
  • 服務
  • 資料集
    • 臨床領域數據
    • 計費數據
    • 藥房數據
    • 患者主導的數據

第5章：北美真實世界數據解決方案市場：基於應用的估算和趨勢分析

  • 按應用領域分類的市場佔有率和波動分析（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按應用領域分類，2021-2033年
  • 藥物研發及核准
  • 醫療設備的研發與核准
  • 報銷、適用範圍和監管決策
  • 上市後安全性與不利事件監測

第6章：北美真實世界數據解決方案市場：按最終用途分類的估算和趨勢分析

  • 最終用途：儀錶板
  • 按應用領域分類的市佔率波動分析（2025 年和 2033 年）
  • 市場規模、預測和趨勢分析：按最終用途分類，2021-2033 年
  • 醫療保健公司（製藥、生物製藥、醫療設備）
    • 臨床研究
    • 商業領域（包括行銷等）
    • HEOR
    • 其他（例如，市場進入）
  • 健康保險提供者
  • 醫療服務提供方
  • 其他

第7章：北美真實世界數據解決方案市場：按治療領域分類的估算與趨勢分析

  • 按治療區域分類的市場佔有率和波動分析（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：依治療領域分類，2021-2033年
  • 腫瘤學
  • 循環系統
  • 糖尿病
  • 神經病學
  • 精神病學
  • 呼吸系統
  • 其他治療領域（免疫學、胃腸病學等）
  • 其他治療領域（免疫學、胃腸病學等）的市場估算、預測和展望（2021-2033 年）

第8章：北美真實世界數據解決方案市場：國別估算與趨勢分析

  • 各國市場概覽
  • 各國市場：要點
  • 美國
    • 主要國家的趨勢
    • 法律規範
    • 競爭考察
  • 加拿大
    • 主要國家的趨勢
    • 法律規範
    • 競爭考察
  • 墨西哥
    • 主要國家的趨勢
    • 法律規範
    • 競爭考察

第9章 競爭情勢

  • 2025年公司市場分析
  • 公司分類
  • 公司簡介列表
    • IQVIA
    • Merative
    • PPD Inc.（now part of Thermo Fisher）
    • Parexel International Corporation
    • Icon Plc
    • Oracle
    • Syneos Health
    • Cegedim Health Data
    • Medpace
    • Optum Inc.（UnitedHealth Group）
    • SAS Institute Inc.
    • Cognizant
    • Aetion, Inc.（acquired by Datavant in May 2025）
    • Flatiron Health
    • Cytel Inc.
    • Trinity
    • NTT Data Inc.
Product Code: GVR-4-68040-878-1

North America Real World Evidence Solutions Market Summary

The North America real world evidence solutions market size was estimated at USD 1.34 billion in 2025 and is projected to reach USD 2.52 billion by 2033, growing at a CAGR of 8.29% from 2026 to 2033. Market growth is driven by the increasing use of real-world data in regulatory decision-making, the rising demand for value-based healthcare, and the need among pharmaceutical and biotechnology companies to generate post-market evidence on drug safety and effectiveness.

The North America Real-World Evidence (RWE) solutions industry is growing, driven by strong regulatory support for the adoption of RWE solutions and expanding investments in biomedical and translational research. For instance, according to the National Center for Science and Engineering Statistics, in 2024, R&D expenditures in health sciences reached USD 38.5 billion, up USD 2.8 billion from 2023, while biological and biomedical sciences accounted for USD 20.8 billion, up USD 1.3 billion from 2023. Together, these fields represented 50% of total higher education R&D spending. The growth in academic medical center research and life sciences funding supports a greater generation of real-world data, observational studies, and clinical research outputs, thereby increasing demand for advanced RWE analytics and evidence-generation platforms.

Moreover, the shift from volume-based to value-based care is anticipated to fuel market growth. The rising geriatric population and the increasing prevalence of chronic diseases further drive market expansion. In addition, the region's strong market position is supported by the presence of key industry players across the U.S. and Canada. Favorable government regulations and the growing number of RWE service providers in the region are expected to further accelerate market growth.

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America real world evidence solutionsmarket report based on service, component, application, end use, therapeutic area, and region:

Market Report Segmentation

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Services
  • Data Sets
    • Clinical Settings Data
    • Claims Data
    • Pharmacy Data
    • Patient-Powered Data
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Development & Approvals
  • Medical Device Development & Approvals
  • Reimbursement/Coverage and Regulatory Decision Making
  • Post Market Safety & Adverse Events Monitoring
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
    • Clinical research
    • Commercial (inclusive of marketing, etc.)
    • HEOR
    • Others (market access, etc.)
  • Healthcare Payers
  • Healthcare Providers
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiology
  • Neurology
  • Diabetes
  • Psychiatry
  • Respiratory
  • Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • U.S.
  • Canada
  • Mexico

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Component
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Therapeutic Area
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High adoption of electronic health records (EHRs) and digital health technologies
      • 3.2.1.2. Advancements in big data analytics, artificial intelligence, and cloud-based healthcare platforms
      • 3.2.1.3. Increasing demand for real-world data to support drug development and clinical research
      • 3.2.1.4. Expansion of healthcare databases, patient registries, and claims data sources
      • 3.2.1.5. Growing need for cost-effective healthcare and value-based care models
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Data privacy and security concern
      • 3.2.2.2. High cost of implementing advanced analytics and data integration platforms.
      • 3.2.2.3. Data quality and interoperability challenges
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Pricing Analysis
    • 3.2.6. Emerging Trends
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape
    • 3.3.3. Market Opportunity analysis
    • 3.3.4. Market Challenges analysis

Chapter 4. North America Real World Evidence Solutions Market: Component Estimates & Trend Analysis

  • 4.1. Component Segment Dashboard
  • 4.2. Component Market Share Movement Analysis, 2025 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Component, 2021 to 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Data Sets
    • 4.5.1. Data sets market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2. Clinical Settings Data
      • 4.5.2.1. Clinical Settings Data market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3. Claims Data
      • 4.5.3.1. Claims Data market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.4. Pharmacy Data
      • 4.5.4.1. Pharmacy Data market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.5. Patient-Powered Data
      • 4.5.5.1. Patient Powered Data market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. North America Real World Evidence Solutions Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Application Market Share Movement Analysis, 2025 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Drug Development & Approvals
    • 5.4.1. Drug development & approval market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Medical Device Development & Approvals
    • 5.5.1. Medical device development & approvals market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Reimbursement/Coverage and Regulatory Decision Making
    • 5.6.1. Reimbursement/Coverage and Regulatory Decision Making market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Post Market Safety & Adverse Events Monitoring
    • 5.7.1. Post Market Safety & Adverse Events Monitoring market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. North America Real World Evidence Solutions Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Dashboard
  • 6.2. End Use Market Share Movement Analysis, 2025& 2033
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
    • 6.4.1. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device) market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Clinical research
      • 6.4.2.1. Clinical research market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Commercial (inclusive of marketing, etc.)
      • 6.4.3.1. Commercial (inclusive of marketing, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. HEOR
      • 6.4.4.1. HEOR market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Others (market access, etc.)
      • 6.4.5.1. Others (market access, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Healthcare Payers
    • 6.5.1. Healthcare Payers market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Healthcare Providers
    • 6.6.1. Healthcare Providers market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. North America Real World Evidence Solutions Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Therapeutic Area Segment Dashboard
  • 7.2. Therapeutic Area Market Share Movement Analysis, 2025 & 2033
  • 7.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Cardiology
    • 7.5.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Diabetes
    • 7.6.1. Diabetes market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Neurology
    • 7.7.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Psychiatry
    • 7.8.1. Psychiatry market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. Respiratory
    • 7.9.1. Respiratory market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.10. Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
  • 7.11. Other Therapeutic Areas (Immunology, Gastroenterology, etc.) market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. North America Real World Evidence Solutions Market: Country Estimates & Trend Analysis

  • 8.1. Country Market Dashboard
  • 8.2. Country Market: Key Takeaways
  • 8.3. U.S.
    • 8.3.1. Key country dynamic
    • 8.3.2. Regulatory framework
    • 8.3.3. Competitive insights
    • 8.3.4. U.S. Real World Evidence Solutions market estimates and forecasts, 2021-2033 (USD Million)
  • 8.4. Canada
    • 8.4.1. Key country dynamic
    • 8.4.2. Regulatory framework
    • 8.4.3. Competitive insights
    • 8.4.4. Canada Real World Evidence Solutions market estimates and forecasts, 2021-2033 (USD Million)
  • 8.5. Mexico
    • 8.5.1. Key country dynamic
    • 8.5.2. Regulatory framework
    • 8.5.3. Competitive insights
    • 8.5.4. Mexico Real World Evidence Solutions market estimates and forecasts, 2021-2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Market Position Analysis, 2025
  • 9.2. Company Categorization
  • 9.3. Company Profiles/Listing
    • 9.3.1. IQVIA
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Product benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Merative
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. PPD Inc. (now part of Thermo Fisher)
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Parexel International Corporation
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Icon Plc
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Oracle
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Syneos Health
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Cegedim Health Data
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Medpace
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Optum Inc. (UnitedHealth Group)
      • 9.3.10.1. Overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. SAS Institute Inc.
      • 9.3.11.1. Overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Cognizant
      • 9.3.12.1. Overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Aetion, Inc. (acquired by Datavant in May 2025)
      • 9.3.13.1. Overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Flatiron Health
      • 9.3.14.1. Overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Cytel Inc.
      • 9.3.15.1. Overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Trinity
      • 9.3.16.1. Overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. NTT Data Inc.
      • 9.3.17.1. Overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives

List of Table

  • Table 1 List of abbreviations
  • Table 2 List of secondary data sources
  • Table 3 North America Real World Evidence Solutions market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
  • Table 5 North America Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 7 North America Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 8 U.S Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
  • Table 9 U.S Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
  • Table 10 U.S Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 11 U.S Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 12 Canada Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
  • Table 13 Canada Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
  • Table 14 Canada Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Canada Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 16 Mexico Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
  • Table 17 Mexico Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
  • Table 18 Mexico Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Mexico Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 North America Real World Evidence Solutions market: Market outlook
  • Fig. 5 North America Real World Evidence Solutions market: Segment outlook
  • Fig. 6 North America Real World Evidence Solutions market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 North America Real World Evidence Solutions Market Driver Impact
  • Fig. 9 North America Real World Evidence Solutions Market Restraint Impact
  • Fig. 10 North America Real World Evidence Solutions market, Component outlook key takeaways (USD Million)
  • Fig. 11 North America Real World Evidence Solutions market: Component movement analysis (USD Million)
  • Fig. 12 Services market, 2021 - 2033 (USD Million)
  • Fig. 13 Data sets market, 2021 - 2033 (USD Million)
  • Fig. 14 Clinical settings data market, 2021 - 2033 (USD Million)
  • Fig. 15 Claim data market, 2021 - 2033 (USD Million)
  • Fig. 16 Pharmacy market, 2021 - 2033 (USD Million
  • Fig. 17 Patient-powered data market, 2021 - 2033 (USD Million)
  • Fig. 18 North America Real World Evidence Solutions market, Application outlook: Key takeaways, (USD Million)
  • Fig. 19 North America Real World Evidence Solutions market: Application movement analysis (USD Million)
  • Fig. 20 Drug development & approvals market, 2021 - 2033 (USD Million)
  • Fig. 21 Medical device development & approvals market, 2021 - 2033 (USD Million)
  • Fig. 22 Reimbursement/coverage & regulatory decision-making market, 2021 - 2033 (USD Million)
  • Fig. 23 Post market safety & adverse events monitoring market, 2021 - 2033 (USD Million)
  • Fig. 24 North America Real World Evidence Solutions market, End use outlook key takeaways (USD Million)
  • Fig. 25 North America Real World Evidence Solutions market: End use movement analysis (USD Million)
  • Fig. 26 Healthcare companies' market, 2021 - 2033 (USD Million)
  • Fig. 27 Clinical research market, 2021 - 2033 (USD Million)
  • Fig. 28 Commercial research market, 2021 - 2033 (USD Million)
  • Fig. 29 HEOR market, 2021 - 2033 (USD Million)
  • Fig. 30 Others market, 2021 - 2033 (USD Million)
  • Fig. 31 Healthcare payers' market, 2021 - 2033 (USD Million)
  • Fig. 32 Healthcare providers market, 2021 - 2033 (USD Million)
  • Fig. 33 Others market, 2021 - 2033 (USD Million)
  • Fig. 34 North America Real World Evidence Solutions market, Therapeutic area outlook key takeaways (USD Million)
  • Fig. 35 North America Real World Evidence Solutions market: Therapeutic area movement analysis, (USD Million)
  • Fig. 36 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 37 Cardiology market, 2021 - 2033 (USD Million)
  • Fig. 38 Neurology market, 2021 - 2033 (USD Million)
  • Fig. 39 Diabetes market, 2021 - 2033 (USD Million)
  • Fig. 40 Psychiatry market, 2021 - 2033 (USD Million)
  • Fig. 41 Respiratory market, 2021 - 2033 (USD Million)
  • Fig. 42 Other therapeutic areas market, 2021 - 2033 (USD Million)
  • Fig. 43 Country marketplace: Key takeaways
  • Fig. 44 North America Real World Evidence Solutions market: Country outlook, 2025 & 2033
  • Fig. 45 U S Real World Evidence Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Canada Real World Evidence Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Mexico Real World Evidence Solutions market estimates and forecasts, 2021 - 2033 (USD Million)